MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: mii-exa-molgen-medikationsempfehlung-fgfr2-fusion

Raw xml | Download


<Task xmlns="http://hl7.org/fhir">
  <id value="mii-exa-molgen-medikationsempfehlung-fgfr2-fusion"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/medikationsempfehlung|2027.0.0-ballot.1"/>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/medication-recommendation|3.0.0"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: Task mii-exa-molgen-medikationsempfehlung-fgfr2-fusion</b></p><a name="mii-exa-molgen-medikationsempfehlung-fgfr2-fusion"> </a><a name="hcmii-exa-molgen-medikationsempfehlung-fgfr2-fusion"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profiles: <a href="StructureDefinition-mii-pr-molgen-medikationsempfehlung.html">MII PR MolGen Medikationsempfehlung</a> version: 2027.0.0-ballot.1, <a href="http://hl7.org/fhir/uv/genomics-reporting/STU3/StructureDefinition-medication-recommendation.html">Medication Recommendation</a> version: 3.0.0</p></div><p><b>basedOn</b>: <a href="ServiceRequest-mii-exa-molgen-anforderung-fgfr2-fusion.html">ServiceRequest Molecular genetic test (procedure)</a></p><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title="Codes:{http://loinc.org LA26421-0}">Hochselektive FGFR-Inhibitor-Therapie</span></p><p><b>for</b>: <a href="Patient-mii-exa-molgen-patient-fgfr2-fusion.html">Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))</a></p><p><b>reasonReference</b>: <a href="Observation-mii-exa-molgen-therapeutische-implikation-fgfr2-fusion.html">Observation Therapeutic Implication</a></p></div>
  </text>
  <basedOn>🔗 
    <reference
               value="ServiceRequest/mii-exa-molgen-anforderung-fgfr2-fusion"/>
  </basedOn>
  <status value="requested"/>
  <intent value="proposal"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA26421-0"/>
      <display value="Consider alternative medication"/>
    </coding>
    <text value="Hochselektive FGFR-Inhibitor-Therapie"/>
  </code>
  <for>🔗 
    <reference value="Patient/mii-exa-molgen-patient-fgfr2-fusion"/>
  </for>
  <reasonReference>🔗 
    <reference
               value="Observation/mii-exa-molgen-therapeutische-implikation-fgfr2-fusion"/>
  </reasonReference>
</Task>